Hot Flushes in Breast Cancer Patients

Hot flushes or hot flashes in breast cancer patientscompletion of treatment with a seventy five percent
are a common problem.or greater reduction in hot flushes from that womens
Many breast cancers are sensitive to circulatingstarting point.
estrogen levels and for many women, suppressingIf the treatment they were on worked well the
the production or the effects of estrogen on thewomen were given another three months of the
body is a major strategy in their treatment. A lack ofsame medication and dose. If they did not get
estrogen will produce symptoms identical to thebenefit after three months then they were given
menopause and the most unpleasant of these are20mg a day of Megace on top of what they were
hot flushes, sweats or hot flashes.already taking.
A new research project has looked at the effect ofReduction of flushings of seventy fiver percent or
a drug called Megace or megesterol acetate inmore was reported ino only 14% of those women
treating hot flushes in women with breast cancer.who were on placebo medicationo 65% of those
They studied nearly three hundred patients withwomen who were on the 20 mg doseo 48% of the
breast cancer who had completed surgery andwomen who were on the 40 mg dose of drug
chemotherapy and at least four months of tamoxifenIn addition, most successes at three months were
treatment for their condition.maintained at six months in seventy seven percent
Before they took part in the study the women hadof the women on 20 mg and in eighty one percent
to have experienced at least ten hot flashes of anyof the women on 40 mg per day - but there was no
severity or at least five severe episodes eachsignificant impact on other menopausal symptoms like
week.When the research data was looked at, eightyvaginal dryness or joint pains.
five percent of the women who took part were onFor the women taking Megace the main side effects
tamoxifen, and forty percent had more than sixtywere fluid retention and weight gain, fatigue and
hot flushes per week. Three quarters of them hadsometimes mild depression.
experienced sweats and flashes for more than sixThe researchers concluded that Megace was very
months before they started in the study.successful in alleviating sweats and flushes in breast
The women were divided into three groups. Onecancer survivors with lasting results at 6 months.
group were given a placebo tablet, one group gotThey recommended the twenty milligram dose for
20mg of Megace and the other received 40mg ofmost women and said that this treatment should be
Megace each day. They all took their medicine forconsidered for all women with menopause flushing
three months. A good outcome was defined assymptoms after breast cancer treatment.